Design Therapeutics, Inc.
Status: Publicly traded
Direct answer
Design Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DSGN.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac,...
Can you invest in Design Therapeutics, Inc.?
Yes. Design Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DSGN.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Design Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.